Sangamo BioSciences Inc
Most Recent
Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses
Sangamo Therapeutics (SGMO) stock rose ~16% in afternoon trading. SGMO released its Q2 earnings results on August 8 after the market closed.
Why Sangamo Therapeutics Stock Is Down More than 22% Today
Today, Sangamo Therapeutics (SGMO) stock is down over 22% in afternoon trading. Yesterday, SGMO stock closed at $19.05.
How Are Sangamo Therapeutics’ Earnings and Expenses Trending?
In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.
A Financial Overview of Sangamo Therapeutics in December 2018
In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.
Taking Stock of Sangamo’s Financial Performance
In this series, we explore Sangamo’s financials, analysts’ views on the stock, and the company’s valuation metrics.
CRISPR Therapeutics: Analysts’ View in November
On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8.
Audentes Therapeutics’ Promising Product Pipeline
In this series, we’ll take a look at six stocks with a focus on gene therapy that have promising products in their pipelines.
How CRISPR Therapeutics Is Positioned in September
CRISPR Therapeutics (CRSP) reported net collaboration revenues of $1.1 million in the second quarter of 2018 compared to $3.6 million in the second quarter of 2017.
Bluebird Bio’s Valuation on September 6
Bluebird Bio (BLUE) reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline year-over-year.
CRISPR Stock Has Seen Soild Growth in the Last 12 Months
CRISPR Therapeutics has risen 24% between May 11 and May 17.
Analysts’ Recommendations for Bioverativ in January 2018
Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock.
The Evolution of Hemophilia Treatment—And What It Means for BioMarin
BioMarin’s BMN 270 is a gene therapy being investigated for hemophilia A. On April 20, it announced early data of the phase-1 and phase-2 study of BMN 270.
Could Gene Therapy Be a Next-Generation Treatment for Hemophilia?
Gene therapy is the emerging platform for hemophilia care. If approved, it would be a paradigm.
